Longboard Pharmaceuticals (LBPH) has issued an update.
The FDA has awarded Breakthrough Therapy designation to bexicaserin for treating seizures in DEE patients aged two and above, promising to speed up its development and review. Longboard Pharmaceuticals plans to launch a global Phase 3 trial of bexicaserin later in the year and release more data on another drug, LP659, following the success of its Phase 1 study. However, these compounds are still investigational and not yet approved. Longboard cautions that forward-looking statements involve risks and uncertainties that could affect actual outcomes, including the possibility that drugs recognized as Breakthrough Therapies may not ultimately prove significantly better than existing therapies.
For detailed information about LBPH stock, go to TipRanks’ Stock Analysis page.
